Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
Holding IONS?
Track your performance easily
IONS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$32.26 - $52.49
Previous CloseN/A
Volume126.35K
Average Volume (3M)1.55M
Market Cap
$5.10B
Enterprise Value$5.45B
Total Cash (Recent Filing)$665.22M
Total Debt (Recent Filing)$587.92M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Feb 19, 2025EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding157,897,300
10 Day Avg. Volume1,523,947
30 Day Avg. Volume1,548,773
Standard Deviation0.09
R-Squared0.04
Alpha-0.00904
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.53
Price to Cash Flow (P/CF)-11.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue6.79
Enterprise Value/Gross Profit7.01
Enterprise Value/Ebitda-20.14
Forecast
1Y Price Target
$60.71Price Target Upside88.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Ionis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentsThe pelacarsen data readout is expected to attract substantial investor interest as it could be the first entry into the untapped Lp(a) market.
Financial PerformanceIonis Pharmaceuticals is expected to achieve multi-billion dollar revenue from several streams, setting a strong financial outlook for the company.
Product LaunchesExpectations are for the FDA to approve donidalorsen as the company's second solo drug, which is anticipated to boost the company's growth.
Bears Say
Financial PerformanceTRYNGOLZA revenues are modeled at $27M, just below the current expectations.
Revenue ImpactThe launch of eplontersen ATTR-CM has been delayed to 2027, which impacts potential revenue timelines.
Sales DeclineSpinraza revenue was below consensus as OUS sales decreased due to an annual order from a single country that did not recur in 2024.
---
Ownership Overview
0.74% Insiders
39.51% Mutual Funds
0.23% Other Institutional Investors
44.65% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IONS FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $32.26 and its highest was $52.49 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Ionis Pharmaceuticals’s market cap is $5.10B.
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is Feb 19, 2025 which is in 32 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.126 by $0.176.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -1.11.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 157,897,300 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.126. Following the earnings report the stock price went up 0.619%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Currently, no hedge funds are holding shares in IONS
---
Ionis Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$60.71 (88.07% Upside)
$60.71 (88.07% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 531.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $181.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 16.3%
Last 30 Days ▲ 16.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.74%
12-Months-Change
Fundamentals
Return on Equity
-73.33%
Trailing 12-Months
Asset Growth
5.01%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
---
IONS Company Deck
---
IONS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with substantial progress in pipeline development and upcoming product launches. Despite a slight decrease in quarterly revenue and increased operating expenses, the company is well-positioned for future growth with a strong cash position and strategic investments.Read More>---
IONS Revenue Breakdown
60.82% R&D
39.18% Commercial
---
IONS Stock 12 Month Forecast
Average Price Target
$60.71
▲(88.07% Upside)
Technical Analysis
Alnylam Pharma
―
Sarepta Therapeutics
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Regeneron
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering IONS
1 Year
1 Year Success Rate
11/16 ratings generated profit
1 Year Average Return
+15.17%
reiterated a buy rating 2 months ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +15.17% per trade.
---